The Iowa Continuity of Care study: Background and methods

American Journal of Health-System Pharmacy

Volumn 65, Issue 17, 2008, Pages 1631-1642

  Carter, Barry L ^a,b,f   Farris, Karen B ^a   Abramowitz, Paul W ^a,c   Weetman, David B ^a,d   Kaboli, Peter J ^b   Dawson, Jeffrey D ^e   James, Paul A ^b   Christensen, Alan J ^b   Brooks, John M ^e  

^a Department of Pharmacy Practice

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^d University of Iowa Hospitals and Clinics ^*

^e UI

^f UNIVERSITY OF IOWA   (United States)

Author keywords

Communication; Errors, medication; Hospitals; Patient care; Pharmaceutical services; Pharmacists, hospital; Pharmacy, institutional, hospital; Professional relations

Indexed keywords

ARTICLE; CASE MANAGER; HUMAN; INTERPERSONAL COMMUNICATION; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COUNSELING; PATIENT EDUCATION; PHARMACIST; PRIORITY JOURNAL;

EID: 51649126721     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070600     Document Type: Article

References (72)

1. Gurwitz JH, Field TS, Harrold LR et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003; 289:1107-16.
2. Forster AJ, Murff HJ, Peterson JF et al. The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med. 2003; 138:161-7.
3. Himmel W, Tabache M, Kochen MM. What happens to long-term medication when general practice patients are referred to hospital. Eur J Clin Pharmacol. 1996; 21:178-81.
4. Beers M, Sliwkowski J, Brooks J. Compliance with medication orders among elderly after hospital discharge. Hosp Formul. 1992; 27:720-4.
5. Joint Commission. 2008 National patient safety goals manual. www.jointcommission.org/NR/rdonlyres/82B717D8-B16A-4442-AD00-CE3188C2F00A/0/ 08_HAP_NPSGs_Master.pdf (accessed 2008 Jul 17).
6. Schnipper JL, Kirwin JL, Cotugno MC et al. Role of pharmacist counseling in preventing adverse drug events after hospitalization. Arch Intern Med. 2006; 166:565-71.
7. Dudas V, Bookwalter T, Kerr KM et al. The impact of follow-up telephone calls to patients after hospitalization. Am J Med. 2001; 111(9B):26S-30S.
8. Moore C, McGinn T, Halm E. Tying up loose ends: discharging patients with unresolved medical issues. Arch Intern Med. 2007; 167:1305-11.
9. Kaushal R, Bates DW. The clinical pharmacist's role in preventing adverse drug events. In: Making health care safer: a critical analysis of patient safety practices. Evidence report/technology assessment no. 43. Publication no. 01-E058, Rockville, MD: Agency for Healthcare Research and Quality; 2001; 71-7. www.ahrq.gov/clinic/ptsafety/chap7.htm.
10. Murff HJ, Bates DW. Information transfer. In: Making health care safer: a critical analysis of patient safety practices. Evidence report/technology assessment no. 43. Publication no. 01-E058. Rockville, MD: Agency for Healthcare Research and Quality; 2001; 471-6. www.ahrq.gov/clinic/ptsafety/chap42a.htm.
11. Smith L, McGowan L, Moss-Barclay C et al. An investigation of hospital generated pharmaceutical care when patients are discharged home from hospital. Br J Clin Pharmacol. 1997; 44:163-5.
12. Kuehl AK, Chrischilles EA, Sorofman BA. System for exchanging information among pharmacists in different practice environments. Am J Health-Syst Pharm. 1998; 55:1017-24.
13. Cromarty E, Downie G, Wilkinson S et al. Communication regarding the discharge medications of elderly patients: a controlled trial. Pharm J. 1998; 260:62-4.
14. Chrischilles EA, Carter BL, Lund BC et al. Evaluation of the Iowa Medicaid pharmaceutical case management program. J Am Pharm Assoc. 2004; 44:337-49.
15. Ellis SL, Billups SJ, Malone DC et al. Types of interventions made by clinical pharmacists in the IMPROVE study. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy. 2000; 20:429-35.
16. Ellis SL, Carter BL, Malone DC et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy. 2000; 20:1508-16.
17. Bond CA, Raehl CL, Franke T. Clinical pharmacy services and hospital mortality rates. Pharmacotherapy. 1999; 19:556-64.
18. Bond CA, Raehl CL, Franke T. Interrelationships among mortality rates, drug costs, total cost of care, and length of stay in United States hospitals: summary and recommendations for clinical pharmacy services and staffing. Pharmacotherapy. 2001; 21:129-41.
19. Bond CA, Raehl CL, Franke T. Clinical pharmacy services, hospital pharmacy staffing, and medication errors in United States hospitals. Pharmacotherapy. 2002; 22:134-47.
20. Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med. 1995; 155:1949-56.
21. Leape LL, Cullen DJ, Clapp MD et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999; 282:267-70.
22. Hanlon JT, Weinberger M, Samsa GP et al. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med. 1996; 100:428-37.
23. Schumock GT, Butler MG, Meek PD et al. Evidence of the economic benefit of clinical pharmacy services: 1996-2000. Pharmacotherapy. 2003; 23:113-32.
24. Wilt VM, Gums JG, Ahmed OI et al. Outcome analysis of a pharmacist-managed anticoagulation service. Pharmacotherapy. 1995; 15:732-9.
25. McMullin ST, Hennenfent JA, Ritchie DJ et al. A prospective, randomized trial to assess the cost impact of pharmacist-initiated interventions. Arch Intern Med. 1999; 159:2306-9.
26. Malone DC, Carter BL, Billups SJ et al. An economic analysis of a randomized, controlled, multicenter study of clinical pharmacist interventions for high-risk veterans: the IMPROVE study. Impact of Managed Pharmaceutical Care Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy. 2000; 20:1149-58.
27. Malone DC, Carter BL, Billups SJ et al. Can clinical pharmacists affect SF-36 scores in veterans at high risk for medication-related problems? Med Care. 2001; 39:113-22.
28. Kaboli PJ, Hoth AB, McClimon BJ et al. Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med. 2006; 166:955-64.
29. Lizer MH, Brackbill ML. Medication history reconciliation by pharmacists in an inpatient behavioral health unit. Am J Health-Syst Pharm. 2007; 64: 1087-91.
30. Varkey P, Cunningham J, O'Meara J et al. Multidisciplinary approach to inpatient medication reconciliation in an academic setting. Am J Health-Syst Pharm. 2007; 64:850-4.
31. Zarowitz BJ, Stebelsky LA, Muma BK et al. Reduction of high-risk polypharmacy drug combinations in patients in a managed care setting. Pharmacotherapy. 2005; 25:1636-45.
32. Pfeiffer E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc. 1975; 23:433-41.
33. Katz S, Akpom CA. A measure of primary sociobiological functions. Int J Health Serv. 1976; 6:493-508.
34. Katz S, Ford AB, Moskowitz RW et al. Studies of Illness in the Aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963; 185:914-9.
35. Ruscin JM, Semla TP. Assessment of medication management skills in older outpatients. Ann Pharmacother. 1996; 30:1083-8.
36. Simpson SH, Johnson JA, Farris KB et al., for the SCRIP Investigators. Physician perceptions of enhanced community pharmacist care in cholesterol management: a survey of physicians contacted during the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Can Pharm J. 2005; 138:33-9.
37. Carter BL, Helling DK, Jones ME et al. Evaluation of family physician prescribing: influence of the clinical pharmacist. Drug Intell Clin Pharm. 1984; 18:817-21.
38. Ardery G, Carter BL, Milchak JL et al. Explicit and implicit evaluation of physician adherence to hypertension guidelines. J Clin Hypertens (Greenwich). 2007; 9:113-9.
39. Hanlon JT, Schmader KE, Samsa GP et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992; 45:1045-51.
40. Kaboli PJ, Hoth AB, Carter BL et al. Lack of agreement between computerized medication profiles and structured medication histories. J Gen Intern Med. 2002; 17(suppl 1):126. Abstract.
41. Kaboli P, Jaipaul C, Barry W et al. Identification of adverse drug events and medication errors: poor agreement between chart review and physician, nurse, and patient report. J Gen Intern Med. 2003; 18(suppl 1):286.
42. Bates DW, Cullen DJ, Laird N et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995; 274:29-34.
43. Gandhi TK, Weingart SN, Borus J et al. Adverse drug events in ambulatory care. N Engl J Med. 2003; 348:1556-64.
44. Carter BL, Barnette DJ, Chrischilles E et al. Evaluation of hypertensive patients after care provided by community pharmacists in a rural setting. Pharmacotherapy. 1997; 17:1274-85.
45. Chrischilles EA, Helling DK, Aschoff CR. Effect of clinical pharmacy services on the quality of family practice physician prescribing and medication costs. Drug Intell Clin Pharm. 1989; 23:417-21.
46. Chrischilles EA, Segar ET, Wallace RB. Self-reported adverse drug reactions and related resource use. A study of community-dwelling persons 65 years of age and older. Ann Intern Med. 1992; 117:634-40.
47. Gurwitz JH, Field TS, Avorn J et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med. 2000; 109:87-94.
48. Bates DW, Spell N, Cullen DJ et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA. 1997; 277:307-11.
49. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239-45.
50. Manasse HR Jr. Medication use in an imperfect world: drug misadventuring as an issue of public policy, part 2. Am J Hosp Pharm. 1989; 46:1141-52.
51. Manasse HR Jr. Medication use in an imperfect world: drug misadventuring as an issue of public policy, part 1. Am J Hosp Pharm. 1989; 46:929-44.
52. Ives TJ, Bentz EJ, Gwyther RE. Drug-related admissions to a family medicine inpatient service. Arch Intern Med. 1987; 147:1117-20.
53. Beard K. Adverse reactions as a cause of hospital admission in the aged. Drugs Aging. 1992; 2:356-67.
54. Carter BL, Lund BC, Hayase N et al. The extent of potential antihypertensive drug interactions in a Medicaid population. Am J Hypertens. 2002; 15:953-7.
55. Carter BL, Chrischilles EA, Scholz D et al. Extent of services provided by pharmacists in the Iowa Medicaid Pharmaceutical Case Management program. J Am Pharm Assoc. 2003; 43:24-33.
56. Hoth AB, Carter BL, Ness J et al. Development and reliability testing of the clinical pharmacist recommendation taxonomy. Pharmacotherapy. 2007; 27:639-46.
57. Knight EL, Avorn J. Quality indicators for appropriate medication use in vulnerable elders. Ann Intern Med. 2001; 135(8, suppl):703-10.
58. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med. 1997; 157:1531-6.
59. Bandura A, Jeffery RW, Wright CL. Efficacy of participant modeling as a function of response induction aids. J Abnorm Psychol. 1974; 83(1):56-64.
60. Bandura A, ed. Self-efficacy in changing societies. Cambridge, England: Cambridge Univ. Press; 1995.
61. Bandura A. Self-efficacy: the exercise of control. New York: WH. Freeman; 1997.
62. Grymonpre RE, Didur CD, Montgomery PR et al. Pill count, self-report, and pharmacy claims data to measure medication adherence in the elderly. Ann Pharmacother. 1998; 32:749-54.
63. Carter BL, Malone DC, Valuck RJ et al. The IMPROVE study: background and study design. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Am J Health-Syst Pharm. 1998; 55:62-7.
64. Billups SJ, Malone DC, Carter BL. The relationship between drug therapy noncompliance and patient characteristics, health-related quality of life, and health care costs. Pharmacotherapy. 2000; 20:941-9.
65. Steiner JF, Koepsell TD, Fihn SD et al. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care. 1988; 26:814-23.
66. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997; 50:105-16.
67. Farris KB, Kaplan B, Kirking DM. Examination of days supply in computerized prescription claims. J Pharmacoepidemiol. 1994; 3:63-76.
68. Christensen DB, Williams B, Goldberg HI et al. Assessing compliance to antihypertensive medications using computer-based pharmacy records. Med Care. 1997; 35:1164-70.
69. Hamilton RA, Briceland LL. Use of prescription-refill records to assess patient compliance. Am J Hosp Pharm. 1992; 49:1691-6.
70. Monane M, Bohn RL, Gurwitz JH et al. Compliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender, and race. Am J Public Health. 1996; 86:1805-8.
71. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986; 24:67-74.
72. Shea S, Misra D, Ehrlich MH et al. Correlates of nonadherence to hypertension treatment in an inner-city minority population. Am J Public Health. 1992; 82:1607-12.